Pulse Biosciences (PLSE) Q3 2026 earnings — TrendMatrix coverage

Adjusted EPS

-$0.24

Estimate

-$0.29

Surprise

+15.5%

Revenue (period 2026-09-30)

$395,000

Score today

5.1/10

Revenue source: xbrl.

Pulse Biosciences (PLSE) reported a narrower loss than forecast — adjusted EPS of -$0.24 against the -$0.29 estimate (a 15.5% beat on a still-unprofitable quarter).

• Canaccord Genuity Maintains Buy on Pulse Biosciences, Raises Price Target to $74 — benzinga, 2026-11-06
• Pulse Biosciences Presents Six-Month Interim Results from PRECISE-BTN Study — fiscal.ai, 2026-11-06
• Needham Raises Price Target on Pulse Biosciences to $64 — fiscal.ai, 2026-11-06

TrendMatrix currently rates PLSE Sell at 5.1/10; no pre/post engine snapshot brackets this report.

2 of the last 4 quarters beat the estimate; this quarter's +15.5% surprise compares with a +5.4% four-quarter average. Next scheduled report: 2027-02-18.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$53.29

Price target

$54.23

Stop

$49.56

Upside to target

+1.8%

Reward-to-risk

0.1:1

Model outputs from TrendMatrix’s engine as of 2026-11-07 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Medical Instruments & Supplies

Market cap

$3.80B

P/E (fwd)

-45.5

52-week range

$12.56–$58.90

Off 52-week high

9.5%

RSI (14)

63

Volume vs avg

1.10×

Score today

5.1/10